Is It Time To Consider Buying Genovis AB (publ.) (STO:GENO)?
Feb 01
Have your own idea? Try our Stock Screener
Swedish (OMX) Life Sciences Industry Analysis
UpdatedFeb 01, 2025
DataAggregated Company Financials
Companies11
- 7D8.0%
- 3M-4.4%
- 1Y5.7%
- YTD-7.2%
Over the last 7 days, the Life Sciences industry has risen 2.7%, driven by gains from AddLife of 7.7%. The industry has been flat over the past 12 months despite the gain this week. Looking forward, earnings are forecast to grow by 43% annually.
Industry Valuation and Performance
Has the Swedish Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 01 Feb 2025 | SEK 41.3b | SEK 16.7b | -SEK 1,152,911,426.00 | 44.2x | -35.8x | 2.5x |
| Mon, 30 Dec 2024 | SEK 44.2b | SEK 16.7b | -SEK 1,152,911,426.00 | 50.9x | -38.3x | 2.6x |
| Wed, 27 Nov 2024 | SEK 41.3b | SEK 16.8b | -SEK 948,723,426.00 | 47x | -43.5x | 2.5x |
| Fri, 25 Oct 2024 | SEK 42.8b | SEK 16.7b | -SEK 983,175,491.00 | 84.3x | -43.5x | 2.6x |
| Sun, 22 Sep 2024 | SEK 47.1b | SEK 16.7b | -SEK 988,175,491.00 | 57.5x | -47.7x | 2.8x |
| Tue, 20 Aug 2024 | SEK 48.6b | SEK 16.7b | -SEK 1,124,972,538.00 | 62.6x | -43.2x | 2.9x |
| Thu, 18 Jul 2024 | SEK 49.7b | SEK 16.6b | -SEK 1,133,686,510.00 | 61.8x | -43.8x | 3x |
| Sat, 15 Jun 2024 | SEK 43.1b | SEK 16.3b | -SEK 1,188,686,510.00 | 58.1x | -36.2x | 2.6x |
| Mon, 13 May 2024 | SEK 40.3b | SEK 16.3b | -SEK 1,157,635,671.00 | 36.5x | -34.8x | 2.5x |
| Wed, 10 Apr 2024 | SEK 39.6b | SEK 16.0b | -SEK 1,122,792,213.00 | 36x | -35.3x | 2.5x |
| Fri, 08 Mar 2024 | SEK 39.0b | SEK 16.0b | -SEK 1,123,139,210.00 | 39.8x | -34.8x | 2.4x |
| Sun, 04 Feb 2024 | SEK 39.0b | SEK 15.8b | -SEK 1,473,823,683.00 | 55.6x | -26.5x | 2.5x |
| Tue, 02 Jan 2024 | SEK 37.7b | SEK 15.5b | -SEK 1,393,723,683.00 | 45.7x | -27x | 2.4x |
| Thu, 30 Nov 2023 | SEK 34.7b | SEK 15.4b | -SEK 1,395,872,683.00 | 40.9x | -24.9x | 2.2x |
| Sat, 28 Oct 2023 | SEK 27.1b | SEK 15.3b | -SEK 1,256,516,711.00 | 32x | -21.6x | 1.8x |
| Mon, 25 Sep 2023 | SEK 27.5b | SEK 15.1b | -SEK 1,134,516,711.00 | 38.8x | -24.2x | 1.8x |
| Wed, 23 Aug 2023 | SEK 29.6b | SEK 15.1b | -SEK 213,871,038.00 | 41.8x | -138.6x | 2x |
| Fri, 21 Jul 2023 | SEK 31.8b | SEK 14.9b | -SEK 238,476,038.00 | 41.6x | -133.3x | 2.1x |
| Sun, 18 Jun 2023 | SEK 40.1b | SEK 14.6b | -SEK 172,476,038.00 | 38.7x | -232.5x | 2.7x |
| Tue, 16 May 2023 | SEK 39.5b | SEK 14.6b | -SEK 205,506,792.00 | 38.7x | -192x | 2.7x |
| Thu, 13 Apr 2023 | SEK 33.0b | SEK 14.6b | -SEK 57,449,459.00 | 33.6x | -573.8x | 2.3x |
| Sat, 11 Mar 2023 | SEK 34.8b | SEK 14.6b | -SEK 57,185,459.00 | 30.3x | -609x | 2.4x |
| Mon, 06 Feb 2023 | SEK 43.9b | SEK 14.3b | SEK 827.3m | 40.3x | 53x | 3.1x |
| Wed, 04 Jan 2023 | SEK 39.4b | SEK 14.1b | SEK 944.3m | 41.1x | 41.8x | 2.8x |
| Fri, 02 Dec 2022 | SEK 38.2b | SEK 14.1b | SEK 944.3m | 42.1x | 40.5x | 2.7x |
| Sun, 30 Oct 2022 | SEK 33.9b | SEK 13.8b | SEK 743.0m | 55.2x | 45.7x | 2.5x |
| Tue, 27 Sep 2022 | SEK 32.6b | SEK 13.5b | SEK 750.9m | 46.2x | 43.4x | 2.4x |
| Thu, 25 Aug 2022 | SEK 40.4b | SEK 13.5b | SEK 746.2m | 55.8x | 54.2x | 3x |
| Sat, 23 Jul 2022 | SEK 44.3b | SEK 13.1b | SEK 662.4m | 43.3x | 66.9x | 3.4x |
| Mon, 20 Jun 2022 | SEK 43.3b | SEK 13.2b | SEK 753.4m | 39x | 57.5x | 3.3x |
| Wed, 18 May 2022 | SEK 53.3b | SEK 12.9b | SEK 749.4m | 46.9x | 71.1x | 4.1x |
| Fri, 15 Apr 2022 | SEK 65.4b | SEK 11.8b | SEK 732.3m | 54.3x | 89.3x | 5.5x |
| Sun, 13 Mar 2022 | SEK 55.5b | SEK 11.8b | SEK 745.4m | 46.5x | 74.4x | 4.7x |
| Tue, 08 Feb 2022 | SEK 56.0b | SEK 11.3b | SEK 749.1m | 48.3x | 74.8x | 4.9x |
Price to Earnings Ratio
74.8x
Current Industry PE
- Investors are pessimistic on the Swedish Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 2.8x is higher than the industry's current PS ratio of 2.4x.
Past Earnings Growth
- Total earnings for the Life Sciences industry have declined over the last three years, with the industry now making a loss overall.
- Meanwhile revenues have grown 14% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the Swedish Healthcare industry?
| SE Market | 1.14% | |
| Healthcare | 3.30% | |
| Life Sciences | 8.01% | |
| Clinical Research and Equipment | 8.01% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ALIF B AddLife | SEK 151.50 | 7.7% +SEK 1.3b | 36.0% | PE157.8x | |
| BIOT Biotage | SEK 142.00 | 6.9% +SEK 736.5m | -2.7% | PE44.2x | |
| MCAP MedCap | SEK 403.00 | 9.4% +SEK 510.9m | 8.2% | PE26.2x | |
| GENO Genovis AB (publ.) | SEK 30.45 | 28.2% +SEK 438.6m | -34.1% | PE71.4x | |
| BICO BICO Group | SEK 33.38 | 3.9% +SEK 87.5m | -40.6% | PS1x |
